Nervous System News and Research

Latest Nervous System News and Research

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study shows.

18 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Healthy immune response depends on TRPV2 protein

If bad bacteria lurk in your system, chances are they will bump into the immune system's protective cells whose job is gobbling germs.

18 Feb 2010

Cannabis promising for certain pain-related medical conditions, CMCR presents findings to California legislature

Researchers from the University of California's Center for Medicinal Cannabis Research (CMCR) have found "reasonable evidence that cannabis is a promising treatment" for some specific, pain-related medical conditions. Their findings, presented today to the California legislature and public, are included in a report available on the CMCR web site at http://www.cmcr.ucsd.edu

18 Feb 2010

Ibuprofen may reduce risk of Parkinson's disease, says study

New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

18 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

Migraine is seen more frequently in women with MS than those without: Study

Migraine is seen more frequently in women with multiple sclerosis (MS) than those without, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

17 Feb 2010

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Biogen Idec and Facet Biotech Corporation today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFNβ alone in patients with active relapsing forms of MS.

17 Feb 2010

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Alkermes, Inc. today announced positive topline data from a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).

16 Feb 2010

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Simple, inexpensive test to help determine concussion in athletes

A simple test of reaction time may help determine whether athletes have sustained a concussion (also known as mild traumatic brain injury) and when they are ready to play again, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

16 Feb 2010

Research findings highlight the vital need for better secondary stroke prevention

New research finds that one out of 12 people who have a stroke will likely soon have another stroke, and one out of four will likely die within one year. Researchers say the findings highlight the vital need for better secondary stroke prevention. The study is published in the February 16, 2010, issue of Neurology-, the medical journal of the American Academy of Neurology.

16 Feb 2010

Botulinum injection used for cosmetic purposes may reduce migraine headaches

A preliminary study suggests the same type of botulinum injection used for cosmetic purposes may be associated with reduced frequency of migraine headaches that are described as crushing, vicelike or eye-popping (ocular), but not pain that is experienced as a buildup of pressure inside the head, according to a report in the February issue of Archives of Dermatology, one of the JAMA/Archives journals.

15 Feb 2010

TV medical dramas show inaccurate seizure management

Watching TV medical shows might not be the best way to learn what to do when someone has a seizure. Researchers screened the most popular medical dramas and found that doctors and nurses on the shows responded inappropriately to seizures almost half the time, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

15 Feb 2010

National MS Society launches We Keep Moving campaign to capture stories of people living with MS

For every person living with and affected by MS there is a unique story about how they move forward with their lives. That is why the National Multiple Sclerosis Society is launching We Keep Moving, a viewer-driven reality campaign that will capture these stories and perspectives through online videos that chronicle how people across the country keep moving forward while living with MS

15 Feb 2010

Euthymics Bioscience signs LOI to acquire DOV Pharmaceutical

Euthymics Bioscience, Inc., a privately held Delaware corporation, today announced that it has signed a non-binding Letter of Intent (LOI) to merge into and acquire DOV Pharmaceutical, Inc. (DOV), a Delaware corporation currently traded on the Pink Sheets, for $2.0 million in cash plus payment of certain of DOV's expenses. DOV believes that the contemplated $2.0 million cash payment to shareholders represents approximately $0.015 per share of DOV common stock. If the transaction is consummated, it is anticipated that DOV will be renamed Euthymics Bioscience, Inc.

12 Feb 2010

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that it has hired MTS Health Partners, L.P. as strategic advisor to complement and augment the company’s ongoing business development activities.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Nervous System News and Research

Latest Nervous System News and Research

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Healthy immune response depends on TRPV2 protein

Cannabis promising for certain pain-related medical conditions, CMCR presents findings to California legislature

Ibuprofen may reduce risk of Parkinson's disease, says study

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Migraine is seen more frequently in women with MS than those without: Study

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Meda publishes 2009 year-end report

Simple, inexpensive test to help determine concussion in athletes

Research findings highlight the vital need for better secondary stroke prevention

Botulinum injection used for cosmetic purposes may reduce migraine headaches

TV medical dramas show inaccurate seizure management

National MS Society launches We Keep Moving campaign to capture stories of people living with MS

Euthymics Bioscience signs LOI to acquire DOV Pharmaceutical

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Everything you need to know about epilepsy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in